TheraWolf

TheraWolf is a preclinical-stage biotechnology company based in Mainz, Germany, specializing in the development of modular, targeted cancer immunotherapies. The company utilizes a proprietary platform to design precision medicines that deliver therapeutic payloads directly to tumor cells, aiming to trigger a potent immune response while reducing off-target effects. By focusing on high-affinity binding and specific activation mechanisms, TheraWolf seeks to address the limitations of current oncology treatments. The company is currently advancing its lead candidates through early-stage development to treat various solid tumor indications. TheraWolf was founded by experts in antibody engineering and is supported by prominent German venture capital.